Efficacy and safety of Hizentra ®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency

Journal of Clinical Immunology

Volumn 31, Issue 5, 2011, Pages 752-761

  Borte, Michael ^a   Pac, Malgorzata ^b   Serban, Margit ^c   Gonzalez Quevedo, Teresa ^d   Grimbacher, Bodo ^e   Jolles, Stephen ^f   Zenker, Othmar ^g   Neufang Hueber, Jutta ^h   Belohradsky, Bernd ⁱ  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Child Health Institute   (Poland)

^c Clinica III Pediatrie Louis Turcanu   (Romania)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^g CSL BEHRING GMBH   (Germany)

^h CSL Behring AG   (Switzerland)

ⁱ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

local tolerability; pediatric patients; primary immunodeficiency; serum IgG levels; Subcutaneous immunoglobulin (SCIG)

Indexed keywords

HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; APPENDICITIS; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BRONCHITIS; CHILD; CLINICAL ARTICLE; COUGHING; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FATIGUE; FEMALE; HUMAN; HYPERACTIVITY; IMMUNE DEFICIENCY; INJECTION SITE EXTRAVASATION; INJECTION SITE INFLAMMATION; INJECTION SITE MASS; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PEDIATRICS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRESCHOOL CHILD; PRIMARY IMMUNODEFICIENCY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DRUG SUBSTITUTION; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INJECTIONS, SUBCUTANEOUS; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 80255138608     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-011-9557-z     Document Type: Article

References (35)

1. M Berger 2008 Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency Immunol Allergy Clin North Am 28 413 37 18424340 10.1016/j.iac.2008.01.008 (Pubitemid 351522414)
2. RH Buckley 2000 Primary immunodeficiency diseases due to defects in lymphocytes N Engl J Med 343 1313 24 11058677 10.1056/NEJM200011023431806 1:STN:280:DC%2BD3M7ksVSjug%3D%3D
3. H Chapel R Geha F Rosen 2003 Primary immunodeficiency diseases: an update Clin Exp Immunol 132 9 15 12653830 10.1046/j.1365-2249.2003.02110.x 1:STN:280:DC%2BD3s7mslaktg%3D%3D (Pubitemid 36418900)
4. Ochs HD, Smith CIE, Puck JM. Primary immunodeficiency diseases: a molecular and genetic approach. 2nd ed. New York: Oxford University Press Inc, USA; 2007.
5. MA Park JT Li JB Hagan DE Maddox RS Abraham 2008 Common variable immunodeficiency: a new look at an old disease Lancet 372 489 502 18692715 10.1016/S0140-6736(08)61199-X
6. PJ Busse S Razvi C Cunningham-Rundles 2002 Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency J Allergy Clin Immunol 109 1001 4 12063531 10.1067/mai.2002. 124999 1:CAS:528:DC%2BD38XlsVajs7s%3D (Pubitemid 34634312)
7. JB Bussel A Eldor JG Kelton D Varon B Brenner S Gillis, et al. 2004 IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life Thromb Haemost 91 771 8 15045139 1:CAS:528:DC%2BD2cXjsVGrsLw%3D (Pubitemid 38477458)
8. JA Church H Leibl MR Stein IR Melamed A Rubinstein LC Schneider, et al. 2006 Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency J Clin Immunol 26 388 95 16705486 10.1007/s10875-006-9025-3 1:CAS:528:DC%2BD28XmvVaqtrk%3D (Pubitemid 44051386)
9. JA Church M Borte H Taki RP Nelson JW Sleasman AP Knutsen, et al. 2009 Efficacy and safety of Privigen in children and adolescents with primary immunodeficiency Pediatr Asthma Allergy Immunol 22 53 62 10.1089/pai.2009.0005
10. J de Gracia M Vendrell A Alvarez E Pallisa MJ Rodrigo D de la Rosa, et al. 2004 Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency Int Immunopharmacol 4 745 53 15135316 10.1016/j.intimp.2004.02.011 (Pubitemid 38595531)
11. HW Eijkhout JW van der Meer CG Kallenberg RS Weening JT van Dissel LA Sanders, et al. 2001 The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial Ann Intern Med 135 165 74 11487483 1:CAS:528:DC%2BD3MXmtlWktrw%3D (Pubitemid 32738310)
12. ®, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies J Clin Immunol 29 137 44 18814020 10.1007/s10875-008-9231-2 1:CAS:528:DC%2BD1MXht1Ohsbo%3D
13. TG Abrahamsen H Sandersen A Bustnes 1996 Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies Pediatrics 98 1127 31 8951264 1:STN:280:DyaK2s7gvV2rtg%3D%3D (Pubitemid 26399277)
14. HM Chapel GP Spickett D Ericson W Engl MM Eibl J Bjorkander 2000 The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy J Clin Immunol 20 94 100 10821460 10.1023/A:1006678312925 1:CAS:528:DC%2BD3cXjvVClsro%3D (Pubitemid 30314313)
15. A Gardulf U Nicolay O Asensio E Bernatowska A Bock BC Carvalho, et al. 2006 Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies-a prospective, multi-national study J Clin Immunol 26 177 85 16758340 10.1007/s10875-006-9002-x 1:CAS:528:DC%2BD28XltlOisrg%3D (Pubitemid 43869918)
16. S Hansen R Gustafson CI Smith A Gardulf 2002 Express subcutaneous IgG infusions: decreased time of delivery with maintained safety Clin Immunol 104 237 41 12217333 10.1006/clim.2002.5215 1:CAS:528:DC%2BD38XosF2ktr4%3D (Pubitemid 35191099)
17. ER Stiehm AM Casillas JZ Finkelstein KT Gallagher PM Groncy RH Kobayashi, et al. 1998 Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: use of an old method with a new product J Allergy Clin Immunol 101 848 9 9648714 10.1016/S0091-6749(98)70314-8 1:CAS:528:DyaK1cXktlemtbw%3D (Pubitemid 28293195)
18. JB Hagan MB Fasano S Spector RL Wasserman I Melamed MA Rojavin, et al. 2010 Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency J Clin Immunol 30 734 45 20454851 10.1007/s10875-010-9423-4 1:CAS:528: DC%2BC3cXhtFamurnL
19. W Maeder P Lieby A Sebald M Spycher R Pedrussio R Bolli 2010 Local tolerance and stability up to 24 months of a new 20% proline-stabilized polyclonal immunoglobulin for subcutaneous administration Biologicals 39 43 9 10.1016/j.biologicals.2010.11.004
20. M Stucki N Boschetti W Schaefer T Hostettler F Kaesermann T Nowak, et al. 2008 Investigations of prion and virus safety of a new liquid IVIG product Biologicals 36 239 47 18337119 10.1016/j.biologicals.2008.01.004 1:CAS:528:DC%2BD1cXnvVKjsbg%3D
21. ® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clin Immunol. 2011 (in press)
22. European Agency for the Evaluation of Medicinal Products (EMEA), Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the clinical investigation of human normal immunoglobulin for subcutaneous and intramuscular use. EMEA/CPMP/BPWG/282/00. 2002
23. FDA. Safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency. Guidance for industry. 2008.
24. VR Bonagura R Marchlewski A Cox DW Rosenthal 2008 Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection J Allergy Clin Immunol 122 210 2 18602574 10.1016/j.jaci.2008.04.044 1:CAS:528:DC%2BD1cXotlajtrc%3D (Pubitemid 351899076)
25. JS Orange EM Hossny CR Weiler M Ballow M Berger FA Bonilla, et al. 2006 Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology J Allergy Clin Immunol 117 S525 53 16580469 10.1016/j.jaci.2006.01.015 1:CAS:528:DC%2BD28XjtFCqtrk%3D
26. ER Stiehm 1997 Human intravenous immunoglobulin in primary and secondary antibody deficiencies Pediatr Infect Dis J 16 696 707 9239774 10.1097/00006454-199707000-00012 1:STN:280:DyaK2szotlyjtw%3D%3D (Pubitemid 27300708)
27. J Gaspar B Gerritsen A Jones 1998 Immunoglobulin replacement treatment by rapid subcutaneous infusion Arch Dis Child 79 48 51 9771252 10.1136/adc.79.1.48 1:STN:280:DyaK1cvksVWqsw%3D%3D (Pubitemid 28331253)
28. MJ Thomas VM Brennan HH Chapel 1993 Rapid subcutaneous immunoglobulin infusions in children Lancet 342 1432 3 7694025 10.1016/0140-6736(93)92798-X 1:STN:280:DyaK2c%2FkvVynug%3D%3D (Pubitemid 23361272)
29. P Quartier M Debre J De Blic R de Sauverzac N Sayegh N Jabado, et al. 1999 Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients J Pediatr 134 589 96 10228295 10.1016/S0022-3476(99)70246-5 1:CAS:528:DyaK1MXjsFyjsrg%3D (Pubitemid 30180599)
30. HD Ochs S Gupta P Kiessling U Nicolay M Berger 2006 Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases J Clin Immunol 26 265 73 16783465 10.1007/s10875-006- 9021-7 1:CAS:528:DC%2BD28XlvVOks7c%3D (Pubitemid 43901655)
31. M Berger PJ Pinciaro 2004 Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases J Clin Immunol 24 389 96 15163895 10.1023/B:JOCI.0000029108.18995.61 1:CAS:528:DC%2BD2cXkt1Omsb4%3D (Pubitemid 39005571)
32. HD Ochs PJ Pinciaro 2004 Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases J Clin Immunol 24 309 14 15114062 10.1023/B:JOCI.0000025453.23817.3f 1:CAS:528:DC%2BD2cXjsVOisrY%3D (Pubitemid 39030679)
33. A Gardulf U Nicolay D Math O Asensio E Bernatowska A Bock, et al. 2004 Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home J Allergy Clin Immunol 114 936 42 15480339 10.1016/j.jaci.2004.06.053 1:CAS:528:DC%2BD2cXotlClt7s%3D (Pubitemid 39330270)
34. A Gardulf M Borte HD Ochs U Nicolay 2008 Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy Clin Immunol 126 81 8 17964220 10.1016/j.clim.2007.06.009 1:CAS:528:DC%2BD2sXhsVOlsL%2FN (Pubitemid 350278576)
35. R Shapiro 2010 Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis J Clin Immunol 30 301 7 20082124 10.1007/s10875-009-9352-2 1:CAS:528:DC%2BC3cXjs1aqu7o%3D